Search research articles
Contact Us
Filters
Showing results (841-850 of 888) with videos related to
Page
of 89
Sort By:
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
March 20, 2012
[Consensus recommendations of the German Radiology Society (DRG), the German Cardiac Society (DGK) and the German Society for Pediatric Cardiology (DGPK) on the use of cardiac imaging with computed tomography and magnetic resonance imaging]
S Achenbach, J Barkhausen, M Beer, et al.
JCO Precision Oncology
|
February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Maria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Xiangnan Guan, Duanchen Sun, Eric Lu, et al.
European Urology
|
December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials
Guru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Clinical Genitourinary Cancer
|
June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Channing J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
European Urology
|
August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Science Translational Medicine
|
June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma
Natsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Clinical Genitourinary Cancer
|
November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
Neeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Ursula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Page
of 89
Search research articles
Search
Showing results (841-850 of 888) with videos related to
Sort By:
Page
of 89
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
March 20, 2012
[Consensus recommendations of the German Radiology Society (DRG), the German Cardiac Society (DGK) and the German Society for Pediatric Cardiology (DGPK) on the use of cardiac imaging with computed tomography and magnetic resonance imaging]
S Achenbach, J Barkhausen, M Beer, et al.
JCO Precision Oncology
|
February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Maria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Xiangnan Guan, Duanchen Sun, Eric Lu, et al.
European Urology
|
December 5, 2012
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials
Guru Sonpavde, Gregory R Pond, Ronan Fougeray, et al.
Clinical Genitourinary Cancer
|
June 8, 2019
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Channing J Paller, Emmanuel S Antonarakis, Tomasz M Beer, et al.
European Urology
|
August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Science Translational Medicine
|
June 3, 2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma
Natsuko Suwaki, Elsa Vanhecke, Katelyn M Atkins, et al.
Clinical Genitourinary Cancer
|
November 14, 2013
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma
Neeraj Agarwal, Joaquim Bellmunt, Benjamin L Maughan, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Ursula M Vogl, Tomasz M Beer, Ian D Davis, et al.
Page
of 89